Fatigue assessment when treatment is started may be an early clinical marker of adverse event risk, the researchers suggested ...

A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment ...

Prostate cancer is highly treatable when detected early, as it carries a favourable prognosis. Therefore, awareness among ...

Prostate cancer is one of the most common cancers in men but often goes unnoticed. Experts stress early screening, awareness ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

For patients with oligometastatic cancers, particularly kidney or prostate, stereotactic body radiotherapy may frequently ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

For more than 80 years, men have been told that testosterone helps prostate cancer grow. But a very different picture has ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

A new study reveals that only about 1 in 3 patients with prostate cancer have a successful first CT simulation, while 1 in 6 need to be rescheduled for another day.